Genvoya is a combination HIV-1 integrase strand transfer inhibitor (INSTI) and nucleoside analog reverse transcriptase inhibitor (NRTI) used for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 25 kg [1]. It contains the active ingredients elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide [1].
How Does Genvoya Work Against HIV?
Genvoya targets multiple stages of the HIV replication cycle. Elvitegravir inhibits HIV integrase, an enzyme essential for viral DNA integration into the host cell genome. Emtricitabine and tenofovir alafenamide are NRTIs that work by blocking reverse transcriptase, another critical enzyme needed for HIV to convert its RNA into DNA [1]. Cobicistat is a pharmacokinetic enhancer that boosts the blood levels of elvitegravir, allowing for a once-daily dosing regimen [1].
Who is Genvoya Prescribed For?
This medication is indicated for adults and children aged 12 and older who weigh at least 55 pounds (25 kg) and have HIV-1 infection [1]. It is typically used as a complete regimen for the treatment of HIV-1 infection [1].
What Are the Potential Side Effects of Genvoya?
Common side effects associated with Genvoya include nausea, diarrhea, headache, fatigue, and insomnia [1]. More serious potential side effects can include new or worsening kidney problems, decreases in bone mineral density, and lactic acidosis [1]. Liver problems can also occur, particularly in patients with pre-existing liver conditions [1]. It is important for patients to discuss their medical history and any concerns with their healthcare provider.
When Did Genvoya Patents Expire?
The patent landscape for Genvoya is complex, involving patents for the individual components and the combination product. Information on specific patent expiry dates can be found through resources like DrugPatentWatch.com [2]. Patent expiry dates are crucial for determining when generic versions of the drug may become available, potentially impacting pricing and accessibility.
Can Generic Versions of Genvoya Be Made?
Generic versions of Genvoya can be developed and marketed after the expiration of relevant patents and regulatory exclusivities. The availability of generic alternatives typically leads to reduced drug costs.
How Does Genvoya Compare to Other HIV Medications?
Genvoya is one of several combination antiretroviral therapies available for HIV treatment. Other regimens may involve different combinations of INSTIs, NRTIs, or other drug classes. The choice of medication depends on individual patient factors, including viral load, CD4 count, potential drug interactions, and tolerability. For instance, Stribild is another combination medication that contains elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate (TDF), a different prodrug of tenofovir compared to tenofovir alafenamide (TAF) in Genvoya [3]. TAF is generally associated with improved renal and bone safety profiles compared to TDF [3].
What Are the Risks of Taking Genvoya During Pregnancy?
Genvoya is not generally recommended during pregnancy, although it can be used if the benefits outweigh the risks. There is an HIV Pregnancy Registry that monitors the health outcomes of individuals exposed to antiretroviral products, including Genvoya, during pregnancy [1].
What Interactions Does Genvoya Have with Other Drugs?
Genvoya can interact with many other medications due to cobicistat's role as a CYP3A inhibitor. It is essential to inform a healthcare provider about all prescription and over-the-counter medications, as well as herbal supplements, being taken to avoid potentially harmful interactions [1].
What Clinical Data Supports Genvoya's Effectiveness?
The efficacy and safety of Genvoya have been established through clinical trials. Studies such as the DISCOVER trials demonstrated its effectiveness in achieving and maintaining viral suppression in treatment-naive adults [1].
What is the Cost of Genvoya?
The cost of Genvoya can vary significantly depending on insurance coverage, pharmacy pricing, and geographic location. It is often covered by insurance plans, and patient assistance programs may be available to help reduce out-of-pocket expenses [4].
Sources:
[1] https://www.hiv.gov/hiv-basics/treatment/how-hiv-treatment-works/antiretroviral-regimens/genvoya
[2] https://www.drugpatentwatch.com/
[3] https://www.gilead.com/investors/press-room/press-releases/2015/11/fda-approves-genvoyo-the-first-integrase-strand-transfer-inhibitor-based-regimen-with-a-boosted-protease-inhibitor-for-the-treatment-of-hiv-1-infection-in-adults-and-pediatric-patients-aged-12-and-older
[4] https://www.Drugs.com/price-guide/genvoya